(2S)-N-(2-nitrobenzenesulphenyl)pyrrolidine-2-carbonitrile | 65707-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-N-(2-nitrobenzenesulphenyl)pyrrolidine-2-carbonitrile
• 英文别名: (2S)-1-(2-nitrophenyl)sulfanylpyrrolidine-2-carbonitrile
• CAS: 65707-60-0
• 化学式: C₁₁H₁₁N₃O₂S
• 分子量: 249.293
• InChiKey: JYOJNRBNEZRLLK-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  98.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Inhibitors of dipeptidyl peptidase IV
  申请人：——

  公开号：US20030216450A1

  公开（公告）日：2003-11-20

  Compounds according to general formula (1), wherein R 1 is H or CN, X 1 is S, O, SO 2 or CH 2 , X 2 is O, S or CH 2 , X 3 is NR 5 or a carbonyl or thiocarbonyl group and R 4 is R 6 R 7 N, R 8 (CH 2 ) q OC(═O), R 8 (CH 2 ) q OC(═S), R 6 R 7 NC(═O), R 6 R 7 NC(═S); R 8 (CH 2 ) q C(═O), R 8 (CH 2 ) q C(═S) or R 8 (CH 2 ) q SO 2 , m is 1-3 and n is 0-4 are new. The compounds of the invention are inhibitors of dipeptidyl peptidase IV. Pharmaceutical compositions of the compounds of the invention, or pharmaceutically acceptable salts thereof, are useful in the treatment of,inter alia, type 2 diabetes.

  根据通用公式（1），化合物中R1为H或CN，X1为S、O、SO2或CH2，X2为O、S或 ，X3为NR5或羰基或硫代羰基基团，R4为R6R7N、R8( )qOC（═O）、R8( )qOC（═S）、R6R7NC(═O)、R6R7NC(═S)；R8( )qC(═O)、R8( )qC(═S)或R8( )qSO2，m为1-3，n为0-4的新化合物。该发明的化合物是二肽基肽酶IV的抑制剂。该发明的化合物的药用组合物或其药用盐在治疗2型糖尿病等疾病中有用。
• Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents
  申请人：Evans M David

  公开号：US20050004205A1

  公开（公告）日：2005-01-06

  The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein R 1 is H or CN; R 2 is selected from CH 2 R 5 , CH 2 CH 2 R 5 and C(R 3 )(R 4 )—X 2 —(CH 2 ) a R 5 ; R 3 and R 4 are each independently selected from H and Me; R 5 is selected from CON(R 6 )(R 7 ), N(R 8 )C(=0)R 9 , N(R 8 )C(═S)R 9 , N(R 8 )SO 2 R 10 and N(R 8 )R 10 ; R 6 and R 7 are each independently R 11 (CH 2 ) b or together they are —(CH 2 ) 2 -Z-(CH 2 ) 2 — or CH 2 -o-C 6 H 4 -Z-CH 2 —; R 8 is H or Me; R 9 is selected from R 11 (CH 2 ) b , R 11 (CH 2 ) b O and N(R 6 )(R 7 ); R 10 is R 11 (CH 2 ) b ; R 11 is selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; R 12 is selected from H 2 NCH(R 13 )CO, H 2 NCH(R 14 )CONHCH(R 15 )CO, C(R 16 )═C(R 17 )COR 18 and R 19 OCO; R 13 , R 14 and R 15 are selected from the side chains of the proteinaceous amino acids; R 16 is selected from H, lower alkyl (C 1 -C 6 ) and phenyl; R 17 is selected from H and lower alkyl (C 1 -C 6 ); R 18 is selected from H, lower alkyl (C 1 -C 6 ), OH, O-(lower alkyl (C 1 -C 6 )) and phenyl; R 19 is selected from lower alkyl (C 1 -C 6 ), optionally substituted phenyl and R 20 C(=0)OC(R 21 )(R 22 ); R 20 , R 21 and R 22 are each independently selected from H and lower alkyl (C 1 -C 6 ); Z is selected from a covalent bond, —(CH 2 ) c —, —O—, —SO d — and —N(R 10 )—; X 1 is S or CH 2 ; X 2 is O, S or CH 2 ; a is 1, 2 or 3; b is 0-3; c is 1 or 2; and d is 0, 1 or 2.

  本发明涉及一系列具有改进性能的DP-IV抑制剂的前药。这些化合物可用于治疗多种人类疾病，包括糖耐量受损和2型糖尿病。该发明的化合物由通式（1）描述；其中，R1为H或CN；R2选自 R5， R5和C（R3）（R4）-X2-（CH2）aR5；R3和R4各自独立地选自H和Me；R5选自CON（R6）（R7），N（R8）C（=0）R9，N（R8）C（═S）R9，N（R8）SO2R10和N（R8）R10；R6和R7各自独立地为R11（ ）b，或者它们为-（ ）2-Z-（ ）2-或 -o-C6H4-Z- -；R8为H或Me；R9选自R11（ ）b，R11（ ）bO和N（R6）（R7）；R10选自R11（ ）b；R11选自H，烷基，可选择取代的芳基，可选择取代的酰芳基，可选择取代的芳基磺酰基和可选择取代的杂环芳基；R12选自H2NCH（R13）CO，H2NCH（R14）CONHCH（R15）CO，C（R16）═C（R17）COR18和R19OCO；R13，R14和R15选自蛋白质氨基酸的侧链；R16选自H，低烷基（C1-C6）和苯基；R17选自H和低烷基（C1-C6）；R18选自H，低烷基（C1-C6），OH，O-（低烷基（C1-C6））和苯基；R19选自低烷基（C1-C6），可选择取代的苯基和R20C（=0）OC（R21）（R22）；R20，R21和R22各自独立地选自H和低烷基（C1-C6）；Z选自共价键，-（ ）c-，-O-，-SOd-和-N（R10）-；X1为S或 ；X2为O，S或 ；a为1、2或3；b为0-3；c为1或2；d为0、1或2。
• Preparation of Terazole Derivatives
  申请人：Sedelmeier Gottfried

  公开号：US20080200687A1

  公开（公告）日：2008-08-21

  The invention relates to a process for the preparation of (S)-pyrrolidine-1H-tetrazole derivatives of formula wherein R 1 , R 2 and R 3 , independently of one another, represent hydrogen, halogen or an organic radical, in racemic form or as an enantiomer, a tautomer, an analog thereof or a salt thereof.

  本发明涉及一种制备式为（S）-吡咯烷-1H-四唑衍生物的过程，其中R1、R2和R3分别独立地表示氢、卤素或有机基团，以外消旋体形式或对映体、互变异构体、类似物或其盐形式存在。
• INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
  申请人：Ferring B.V.

  公开号：EP1280797A1

  公开（公告）日：2003-02-05
• NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) INHIBITORS AS ANTI-DIABETIC AGENTS
  申请人：Ferring B.V.

  公开号：EP1450794A1

  公开（公告）日：2004-09-01